Clinical Trial Update: A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial is evaluating the combination of sacituzumab govitecan and berzosertib in small cell lung cancer, extrapulmonary small cell neuroend…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Carcinoma Extrapulmonary
• Small Cell Lung Cancer

Drugs mentioned

• Berzosertib (berzosertib)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HRD Cancer, SCLC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING